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ABSTRAK 
Kajian ini bertujuan untuk mengkaji pengaruh faktor-faktor pengurusan 
dalam bentuk kawalan penyeliaan dan pemberian kuasa terhadap prestasi jurujual 
dalam industri farmaseutikal di Malaysia. Kawalan dan pemberian kuasa sering 
dikaitkan sebagai amalan pengurusan yang bertentangan dan jarang dikaji serentak. 
Walau bagaimanapun, pengkaji berpendapat amalan kawalan dan pemberian kuasa 
harus wujud bersama dalam konteks pengurusan moden. Oleh itu, kajian empirikal 
ini bertujuan untuk mengesahkan bahawa amalan kawalan dan pemberian kuasa 
perlu dipraktiskan bersama demi peningkatan prestasi para jurujual. Kajian ini juga 
menyiasat kesan perantaraan perlakuan penjualan adaptif jurujual terhadap 
hubungan antara amalan pengurusan tersebut dengan prestasi jurujual. Di samping 
itu, kajian ini juga mengkaji bagaimana kecerdasan emosi jurujual 
menyerdahanakan hubungan antara perlakuan penjualan adaptif dengan prestasi 
mereka. Penemuan empirikal kajian yang melibatkan 133 jurujual dengan 
menggunakan kaedah Partial Least Square membuktikan bahawa dimensi kawalan 
dan pemberian kuasa yang tertentu boleh wujud bersama. Kawalan aktiviti, amalan 
pemberian kuasa seperti penggalakan penyertaan, pemberian keyakinan dan 
autonomi mempunyai kesan yang signifikan ke atas prestasi jurujual dan perlakuan 
 
 
xviii 
penjualan adaptif mereka. Perlakuan penjualan adaptif jurujual juga didapati 
menunjukkan kesan perantaraan separa dalam hubungan antara kawalan aktiviti, 
penggalakan penyertaan, pemberian keyakinan dan autonomi dengan prestasi 
jurujual. Kecerdasan emosi didapati mempunyai kesan penyerdahanaan ke atas 
hubungan antara perlakuan penjualan adaptif dan prestasi jurujual. Implikasi teori 
dan pengurusan telah dibincangkan. Kekangan kajian dijelaskan dan cadangan 
untuk kajian akan datang juga disarankan. 
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EXAMINING SALESPERSON PERFORMANCE IN PHARMACEUTICAL 
INDUSTRY IN MALAYSIA : INFLUENCE OF CONTROL, 
EMPOWERMENT, ADAPTIVE SELLING BEHAVIOR AND  
EMOTIONAL INTELLIGENCE 
 
ABSTRACT 
This study aims to examine the influence of managerial factors of supervisory 
control and empowerment on salesperson performance in the pharmaceutical 
industry in Malaysia. Control and empowerment were often seen as contradictory 
managerial practices and these practices were rarely studied simultaneously. 
However, scholars opined that control and empowerment practices should co-exist in 
the context of modern management. Thus, this empirical study intends to validate 
that both control and empowerment practices have to be present to enhance 
salesperson performance. This study also investigates the mediating effect of 
salesperson‘s adaptive selling behavior on the relationships between these 
managerial practices and salesperson performance. Besides that, it also examines 
how emotional intelligence of the salesperson moderates the relationship between 
salesperson‘s adaptive selling behavior and salesperson performance. The empirical 
findings involving 133 salespersons using Partial Least Square method revealed that 
certain dimensions of control and empowerment can co-exist. Activity control, 
empowering practices such as promoting participation, expressing confidence and 
providing autonomy were having significant impact on salesperson performance as 
well as on adaptive selling behavior. Adaptive selling behavior partially mediated the 
 
 
xx 
relationship between activity control and salesperson performance, between 
expressing confidence and salesperson performance and between providing 
autonomy and salesperson performance. Emotional intelligence was found to have a 
moderating effect on the relationship between adaptive selling behavior and 
salesperson performance. Theoretical and managerial implications were discussed. 
Research limitations were presented and recommendations for future studies were 
proposed. 
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CHAPTER 1 
 
INTRODUCTION  
 
 
1.0  Introduction 
The first chapter of this thesis presents the background of the study by giving an 
overview of the pharmaceutical industry in Malaysia, its importance in Malaysia and 
the importance of salesperson performance in this particular industry. This chapter 
further discusses the problem statement and the findings of the preliminary study that 
contribute to the development of the research objectives and research questions. 
Following these are the discussion of the scope of the study, the significance of the 
study, the definition of various key terms used and lastly, a brief outline of the 
organization of this thesis. 
1.1 Background of the Study 
The present study aims to examine the influence of sales managerial practices, 
salesperson‘s adaptive selling behavior and emotional intelligence on salesperson 
performance in the pharmaceutical industry in Malaysia. The following subsections 
describe the overview of the pharmaceutical industry in Malaysia, why it is important 
and the importance of salesperson performance in this highly competitive and dynamic 
industry. 
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1.1.1 Overview of Pharmaceutical Industry in Malaysia 
In general, firms in the pharmaceutical industry in Malaysia can be distinctly 
categorized into the local and the foreign multinational firms. All these pharmaceutical 
firms are registered as members with the Pharmaceutical Association of Malaysia 
(PhAMA). These firms offer a broad range of drugs that are regulated by the Drug 
Control Authority (DCA) under the Malaysian Ministry of Health (MOH). Both these 
local and foreign multinational firms play the key roles in managing and controlling a 
number of non-communicable diseases such as diabetes, communicable diseases such 
as typhoid, and potentially life-threatening diseases such as cancer and AIDS.  
According to the Malaysian Organization of Pharmaceutical Industries 
(MOPI), pharmaceutical products can be broadly categorized into four groups, namely 
ethical drugs, over-the-counter (OTC) drugs, traditional medicines and health 
supplements. Ethical drugs are controlled medicines which can only be obtained from 
licensed healthcare professionals. Ethical drugs can be further grouped into Group B 
and Group C drugs, where the former requires a prescription to be purchased while the 
latter does not. Therefore, ethical drugs are also commonly referred to as prescription 
drugs. In general, ethical drugs are mainly the patented innovator drugs, though they 
can also be available in their generic versions if the original patents expire. OTC drugs 
are usually the less expensive drugs used to treat common illnesses. Hence, OTC 
drugs can be purchased from the shelf and used by patients without prescriptions from 
the licensed healthcare professionals. In Malaysia, pharmaceutical products can be 
purchased from retail pharmacies, clinics, hospitals and medical centers. 
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The functions of these pharmaceutical firms can be broadly divided into 
manufacturing, importation and distribution. The local pharmaceutical firms focus 
primarily on manufacturing and marketing of traditional medicines, vitamins, health 
supplements, OTC drugs and generic ethical drugs. Some local pharmaceutical firms 
are also doing contract manufacturing for overseas pharmaceutical firms. These local 
pharmaceutical firms have the capability to produce almost all forms of generic drugs. 
The importation and distribution functions are mainly dominated by the foreign 
multinational pharmaceutical firms which are responsible for bringing to Malaysia a 
variety of internationally accepted and rigorously tested patented ethicaldrugs which 
efficacy, safety,and quality have been proven, backed by their respectively strong 
research and development capabilities (PhAMA, 2012).  
Local pharmaceutical firms which are involved in the production of traditional 
medicines, vitamins, supplements, OTC drugs and generic ethical drugs, have their 
entire value chain from local research and development (R&D) to the sales and 
distribution set up in Malaysia (PhAMA, 2012). However, of all these foreign 
multinational pharmaceutical firms with sales and marketing presence in Malaysia, 
only 13% of them have local manufacturing operations, whereas 7% have 
manufacturing partnership arrangements with local firms. In other words, the 
remaining 80% of the multinational pharmaceutical firms are only involved in 
importing and marketing of life-saving and relatively new drugs in Malaysia. As a 
result, Malaysia still relies quite heavily on imported patented ethical drugs to fulfill 
the needs of the locals to treat contemporary diseases. It is estimated that as much as 
70% of the local demand for ethicaldrugs is imported and that means the price of 
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ethical drugs is relatively expensive and beyond the affordability of the poor (Hassali 
et al., 2009; PhAMA, 2012). 
Both the foreign multinational and local firms play quite distinct yet 
complementary roles and together, they have ensured that the pharmaceutical needs of 
the nation are fulfilled. While the foreign multinational firms have taken up the 
challenge of developing and producing new patented drugs and vaccines for a broad 
type of diseases, local pharmaceutical firms have gone the extra mile to produce the 
generic version of these patented drugs that are more affordable to the people. 
Typically, new drugs have patents valid up to 20 years, which give exclusive rights to 
the patent holders (or the innovators) of the patented drugs to maximize their profits. 
After the patents expire, any local pharmaceutical firm is allowed to manufacture the 
generic version of the patented drugs and market them within Malaysia or overseas at 
much lower prices (Hassali et al., 2009). This opens up an avenue of opportunity for 
local pharmaceutical firms to expand and grow.The local pharmaceutical firms are 
also venturing into the halal drugs market which has created a source of new business 
opportunity with growing exports to the Middle Eastern countries (PhAMA, 2012). 
Globally, the pharmaceutical sales are expected to maintain a robust growth of 
6.9% annually to reach US$1.61 trillion by 2018 (Deloitte, 2015). The percentage of 
generic drugs is expected to increase from 10.0% (in 2014) to 11.4% (in 2018) 
(Evaluate Pharma, 2015). North America‘s market is currently leading the growth 
while the Asia Pacific region holds good growth potential for the future. Being an Asia 
Pacific emerging economy, Malaysia is expected to record a stronger growth during 
this period (PEMANDU, 2013). According to Malaysia Pharmaceuticals & Healthcare 
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Report 2015(BMI Research, 2015), the total pharmaceutical sales in Malaysia is 
estimated to grow at a rate of 9.2%from 2014 to 2015 in local currency.Malaysia‘s 
pharmaceutical market which includes the sales of patented drugs and generic drugs is 
forecast to increase to US$3.54 billion in 2018 with a compoundedannual growth rate 
(CAGR) of 8.6% in local currency (Deloitte, 2015). The contribution of 
pharmaceutical sales to the country‘s gross domestic product (GDP) is expected to 
gradually increase from 0.67% in 2013 to 0.73% in 2018 (PEMANDU, 
2013).According to the statistics from PriceWaterhouseCoopers (PwC, 2012) and the 
surveys conducted by Research And Markets (R&M, 2013) and IMS Health Study 
(IMS, 2014), the forecast positive growth of the pharmaceutical industry is expected to 
be contributed by the growing population, increase of ageing population, changes in 
lifestyles and urbanization which lead to increased incidence of chronic and lifestyle 
diseases across the entire population and the increased awareness of the need to lead a 
healthy lifestyle in order to preserve well-being. 
1.1.2 The Importance of Pharmaceutical Industry in Malaysia 
The importance of the pharmaceutical industry can be seen in several aspects of its 
contributions. The most significant contribution of the pharmaceutical industry is the 
discovery of new drugs which save millions of lives and help those suffering from 
diseases to recover and lead more productive lives.Although it is not entirely 
attributable to the pharmaceutical industry, globally the increase in life expectancy, 
reduction in adult mortality rate andthe reduction in premature death of newborn 
babies are largely contributed by pharmaceutical innovation (Smith, 2012).  
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As the pharmaceutical industry is recognized as one of the most innovative, 
robust and research-intensive sectors in the world, investment in research and 
development (R&D) and high technology manufacturing has been one of the pillars of 
industrialized economies (Smith, 2012). Multinational pharmaceutical firms have 
consistently invested heavily in R&D even in times of economic crisis and in fact, the 
pharmaceutical industry has the highest annual R&D spending among all the high-
technology industries (Smith, 2012).  
Besides the huge positive impact of R&D and manufacturing investments,   the 
pharmaceutical industry also contributes to positive socio-economic impacts such as 
industry-university research collaboration and knowledge transfer. Malaysia has been 
gaining the benefit through the dissemination of knowledge in the form of offshore 
manufacturing activities and technology transfer from the developed countries 
(PEMANDU, 2013). Innovation and technology transfer have enabled people to enjoy 
a better quality of life and enhanced prosperity of the society through improved health, 
competence and knowledge (Smith, 2012). 
Another enormous contribution of the pharmaceutical industry is in the aspect 
of job creation. High-skilled jobs are created directly and indirectly by the 
pharmaceutical industry. Indirect job creation refers to various job opportunities from 
business establishments that are formed to support the pharmaceutical research and 
manufacturing activities such as in the services sectors. The increase in the number of 
direct and indirect employment opportunities has elevated the economic status of the 
people and subsequently contributes to the well-being of the country through the 
collection of income taxes and consumption taxes for the country. 
 
 
7 
The research-based pharmaceutical industry is also a foundation for the 
existence and growth of the generic pharmaceutical industry in Malaysia. It gives a 
positive impact to Malaysia to further improve innovative capacity, through the 
technology diffusion in the development and production of generic drugs. With the 
impending patent expiry of major blockbuster drugs, there is a huge opportunity for 
local pharmaceutical firms in Malaysia to capitalize and tap into the development and 
production of generic drugs business with an estimated total potential value of US$132 
billion for the country (PEMANDU, 2013).  
In an effort to tap the huge market potential to produce generic drugs to 
substitute patented drugs, the government of Malaysia has included healthcare as a key 
focus in its Economic Transformation Programme (ETP) which was launched on 25 
September 2010. ETP aims to accelerate the country‘s economic transformation to 
achieve high-income status by 2020. ETP consists of 12 National Key Economic 
Areas (NKEAs) which represent the key economic sectors of major contributions. 
Healthcare has been targeted as one of the NKEAs due to its robust growth achieved 
over the past decades and the potential to create significant multiplier effects. The 
Healthcare NKEA focuses on bringing both the public and private sectors into 
collaboration and aims to identify initiatives and opportunities, particularly from the 
private sector, to further develop the entire healthcare eco-system in a more organized 
and coherent manner. This Healthcare NKEA is expected to generate RM35.3 billion 
in incremental Gross National Impact (GNI) and 181,000 new jobs by 2020. 
Specifically, the pharmaceutical industry, which is one of the four sectors within the 
Healthcare NKEA, is targeted to increase its GNI contribution by 22% to RM16.6 
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billion, generates tens of thousand of jobs by 2020 and contributes to income taxes for 
the country (IFPMA, 2011; PEMANDU, 2013). 
With the record of strong growth and profitability compared to other economic 
sectors over the years, the healthcare sector is expected to be a powerful engine of 
economic growth for the country (PEMANDU, 2013; PhAMA, 2012). The 
pharmaceutical industry has been delivering strong performance all these years 
(PEMANDU, 2013). It is expected to maintain its importance to the country‘s GDP 
and remain as a crucial contributing industry in Malaysia for many years to come 
(PEMANDU, 2013).  
 
1.1.3 The Importance of Salesperson in Pharmaceutical Industry in Malaysia 
On the global arena, the pharmaceutical industry is among the most dynamic and 
fastest growing industries (R&M, 2013). In view of the high growth potential, global 
pharmaceutical firms are investing and developing new drugs to capture the largest 
share of the markets. In order to achieve the required Return-On-Investment (ROI), 
these pharmaceutical firms are aggressively spending billions of dollars annually in 
marketing new drugs that they develop and manufacture. They employ aggressive 
marketing strategies to reach out to target customers. They use various forms of 
methods and strategies to maximize revenue. Patents of innovator drugs can only last 
up to 20 years which give the drug firms the exclusive rights to market the drugs 
(Hassali et al., 2009). A large amount of money and time are invested in the marketing 
of these patented drugs within this short span of time to maximize the Return-On-
Investment (ROI). When these patents expire, any other pharmaceutical firms have the 
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rights to obtain the formulae to manufacture these drugs as generic versions and sell 
them at greatly discounted prices in comparison to the patented drugs. 
 Similar to other high-technology industries, there is a threat that the 
pharmaceutical industry will decline into a commodity business due to the intense 
competition and price war (Smith, 2012). The competition is particularly severe in 
developing countries such as Malaysia where the demand for generic drugs is 
increasing as the government encourages the proliferation of use of generic drugs due 
to lower cost reason (Hassali et al., 2009). Imported generic drugs from lower cost 
countries are also making inroads into the highly competitive Malaysian 
pharmaceutical market in recent yearsdue to the regional trade initiatives (Hassali et 
al., 2009). The situation worsens with the practice of parallel import of branded drugs 
from less developed countries such as from India (Hassali et al., 2009). Parallel import 
refers to the practice of drug manufacturers to import similar branded products from 
countries in which they can sell at a cheaper price than in Malaysia (Hassali et al., 
2009). While parallel import benefits consumers as the price of the similar products 
can be cheaper, it does not benefit the local manufacturers as it introduces more 
competition and price war in the local market.Some major players may have greater 
control over the market by employing selling strategies that could create competitive 
advantages over their rivals which in turn raise their returns on sales. Selling intensity 
is evident by the increase in the firms‘ business performance which in turn affects the 
pharmaceutical market structure. The Malaysian pharmaceutical market structure is 
classified as highly concentrated (oligopoly), but its market concentration is 
significantly affected by the lagged returns on sales (Chong & Chan, 2014). 
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Generally, in the pharmaceutical industry, there are various types of drugs in 
the market offered by different pharmaceutical manufacturers which are used to treat 
the same type of diseases. Because of the highly competitive nature of the industry, 
pharmaceutical firms focus extensively on their marketing efforts and strategies. By 
providing the necessary information, these pharmaceutical manufacturers rely largely 
on healthcare professionals such as doctors and pharmacists to recommend and 
prescribe their pharmaceutical products to the patients. When products become 
commodities particularly in the generic drugs market, it is getting increasingly more 
difficult to differentiate the products among competing firms. In light of this, the 
competitive differentiation of competing firms has shifted to the uniqueness and 
capabilities of their human capital (Cron & DeCarlo, 2009) and effectiveness of 
managing their human resources (Zakaria, Zainal, & Nasurdin,  2012). According to 
Barney‘s (1991) Resource-Based View, in general, human capital is the biggest asset 
of any firm and they play a pivotal role in creating and sustaining competitive 
advantage for the firms. In view of this, pharmaceutical firms continue to invest in 
developing salespersons in a big way (Zoltners, Sinha, & Lorimer, 2008, 2013) 
because of the effectiveness of personal selling‘s consultative approach and the direct 
human interaction during the selling process with the healthcare professionals. Most 
often, healthcare professionals do not have sufficient knowledge about a newly 
launched pharmaceutical product. Hence, the pharmaceutical salespersons who engage 
in the personal selling process will assist in explaining the new products, clarifying 
concerns, offering alternatives and developing relationships with the healthcare 
professionals (Dogramatzis, 2002). In order to effectively build up the healthcare 
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professionals‘ preference for a particular product, salespersons would repeatedly 
provide the same promotional message to the healthcare professionals over a period of 
time. This approach is called ‗medical detailing‘ (Fanning, Mitchell, & Brideau, 2014) 
and because of this traditional approach, pharmaceutical salespersons are also known 
as ‗medical detailers‘(Rollins & Perri, 2014). 
It is reckoned that the single most effective way to convince the healthcare 
professionals to prescribe products is the use of pharmaceutical salespersons (Zoltners 
et al., 2013). The use of pharmaceutical salespersons is an effective form of personal 
selling where direct one-to-one interaction and communication between the seller and 
the prospective customer takes place (Rollins & Perri, 2014). Personal selling is a 
form of business-to-consumer (B2C) marketing approach. In the business-to-consumer 
(B2C) marketing approach, the salespersons directly interact with the customers who 
are the decision makers. In the pharmaceutical industry, the healthcare professionals 
are the decision makers who recommend drugs to the patients, therefore the use of 
pharmaceutical salespersons to market and promote drugs to healthcare professionals 
plays an extremely important role. 
Specifically in this role, pharmaceutical salespersons are deemed to possess 
vast and up-to-date information about the new drugs that they are promoting. The role 
of the pharmaceutical salespersons is to promote new products and provide important 
information about the new products to the healthcare professionals. The prescribing 
healthcare professionals are the primary decision makers of what drugs to be 
purchased and recommended to their patients. Generally, the sales approach of 
promoting ethical drugs and OTC drugs is slightly different because the decision 
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maker for ethical drugs is usually the doctors while the decision maker for OTC drugs 
is primarily the pharmacists (Rollins & Perri, 2014). Nevertheless, both the doctors 
and pharmacists need to be fully convinced about the efficacy of the drugs in order for 
the drugs to be prescribed to the patients.  
It has been a long history that the pharmaceutical firms have been using the 
personal selling method in promoting their products. This is evident from the sizable 
sales force in the pharmaceutical industry (Zoltners et al., 2008, 2013). Pharmaceutical 
salespersons are the frontline personnel who represent their pharmaceutical firms and 
they connect their firms with the healthcare professionals (Zoltners et al., 2008). In 
this context, the pharmaceutical salespersons play a key influencing role on healthcare 
professionals in their decision-making process of prescribing medicines and at the 
same time they try to build long-term relationships with the healthcare professionals 
(Clark, Vorhies, & Bentley, 2011). In this regard, the relationship quality between the 
pharmaceutical salespersons and the healthcare professionals significantly influences 
the level of trust in the pharmaceutical salespersons (Crosby, Evans, & Cowles, 1990; 
Wright & Lundstrom, 2004).  
Relationship building is a form of investment of time, effort, money, and 
resources by the pharmaceutical salespersons. Relationship building is important 
because in times of heightened competition, pharmaceutical salespersons would most 
likely be able to conduct their business with their customers whom they have 
developed the relationships (Boles, Brashear, Bellenger, & Barksdale, 2000). One of 
the critical success factors in customer relationship sustainability is that the 
pharmaceutical salespersons must be seen as valued partner or consultant in the eyes 
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of the healthcare professionals which can only be achieved if the salespersons possess 
the knowledge and know how and where they can play an important role in their own 
organizations as well as in their customers‘ business (Boles et al., 2000). As healthcare 
professionals are now dealing with more educated patients and are much more pressed 
for time than they used to be, to stay abreast of medical advances, knowledgeable 
salespersons would be most helpful to the healthcare professionals (Hassan, 
2006).Hence, the success of the pharmaceutical salespersons depends largely on the 
relationships they have built with the healthcare professionals (Boles et al., 2000; 
Rhee, 2009; Rollins & Perri, 2014). 
In general, the performance of each salesperson greatly affects the overall 
performance of the firms as their sales performance contributes to their firms‘ revenue 
and sales effectiveness (Babakus, Cravens, Grant, Ingram, & LaForge, 1996). Due to 
this reason, many pharmaceutical firms embark on aggressive marketing strategies by 
increasing their sales force headcounts. However, there isa high cost involved in hiring 
and managing a large sales force (Zoltners et al., 2008, 2013). Furthermore, the 
healthcare professionals are very busy and have limited time interacting with 
pharmaceutical salespersons (Clark et al., 2011; Fanning et al., 2014; Parson & 
Abeele, 1981). Not all healthcare professionals have the same attitude toward the 
pharmaceutical salespersons (Elling, Fogle, McKhann, & Simon, 2002; Wright & 
Lundstrom, 2004). Hence, it is imperative that the pharmaceutical salespersons are 
trained to observe and engage in the best and most effective selling approaches when 
interacting with the healthcare professionals. They use the information they gather and 
understand what it takes to sell the drugs they promote. Conversations and sale pitches 
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need to be carefully tailored to fit the particular personality type of the healthcare 
professionals.  Hence, there is a need to look into enhancing the effectiveness of every 
pharmaceutical salesperson by understanding how an adaptive selling approach can 
lead to increased performance and what drives the salespersons to engage in adaptive 
selling behavior (Blackshear & Plank, 1994). In view of this, the study of 
pharmaceutical salesperson performance has become more important today than it has 
been in the past as what influences the performance of pharmaceutical salespersons 
needs to be understood. Nevertheless, improving salesperson performance remains a 
challenge for many pharmaceutical firms. 
1.2 Problem Statement 
Although the pharmaceutical industry has been recording strong growth over the past 
decades, it is facing challenging times ahead. According to pharmaceutical industry 
analysis adapted from World Preview 2016 (Evaluate Pharma, 2015), although the 
pharmaceutical industry grew at an astounding rate of between 10% to 15% from 2002 
to 2007, but from 2008 onwards, the growth rates have slowed down to between 2% to 
3%. If considering the factor of inflation, the adjusted growth is literally flat.  
 In response to all these challenges, senior management of pharmaceutical firms 
would react by focusing on shrinking the costs (or reducing the bottom-line). As  
investment in R&D dictates a firm‘s future, spendingin R&D is projected to grow 
modestly at 2% per year (Evaluate Pharma, 2015). Hence, most often, it is the 
operational costs that would be reduced (Hassan, 2006). Within the sales organization, 
one easy way is to shrink the sales force and re-assign tasks to existing salespersons 
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(Smith, 2012). However, shrinking sales force is causinghuge negative consequences. 
A study undertook by CEB, a US-based management consulting firm, on thousands of 
companies in the United States revealed that companies which had done well 
consistently were actually competing on non-price differentiators and prioritizing on 
growing revenue (or focusing on growing the top-line) over reducing costs (Raynor & 
Ahmed, 2013). Their study substantiated the need to focus on enhancing the sales 
force as the key business differentiators to grow the firm‘s revenue. 
 It is crucial to have highly capable, effective, smart and high-performing 
salespersons to ensure a firm‘s business sustainability. However, there are several 
management issues and operational challenges facing firms today in using 
salespersons. Managing and motivating salespersons is a challenging task and requires 
a huge amount of time, money and effort (Sinha & Zoltners; 2005). Ineffective and 
unproductive salespersons can cost firms to suffer losses due to loss of customers, loss 
of business opportunities, re-hiring and re-training (Walker, Churchill, & Ford, 1977). 
A firm‘s long-term growth and profitability are highly dependent on the effectiveness 
of its salesperson performance (Churchill, Ford, Hartley, & Walker, 1985). Hence, 
according to Corcoran, Petersen, Baitch, and Barrett (1995), salesperson performance 
warrants rigorous examination when studying factors affecting a firm‘s sales 
performance.       
 A sales job in the pharmaceutical industry is no different compared to other 
industries because in general, a sales job is unique, challenging and stressful by itself. 
Pharmaceutical salespersons are usually independent, proactive and are required to 
spend most of the time in the field meeting healthcare professionals (Kow & Yew, 
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2012). In addition, the expectations from sales management are high because being the 
frontline employees of the pharmaceutical firms, a salesperson performance directly 
impacts the firms‘ sales performance. Coupled with the pressures to meet the monthly 
sales target and rejection from the healthcare professionals, it is no surprise that 
pharmaceutical salespersons may face a high degree of frustration and stress (Sinha & 
Zoltners, 2005). The challenge is how to keep the pharmaceutical salespersons 
constantly motivated, effective, committed and result-oriented in order to achieve the 
best performance.      
 Employing salespersons accounts for a substantial amount in marketing 
expenditures of the firms and it is a significant investment that cannot be ignored 
(Zoltners et al., 2008, 2013). For instance, in the pharmaceutical industry, the budgets 
to maintain a sales force are typically 10% to 20% of the firm‘s sales revenue (Sinha 
& Zoltners; 2005). Although sales force expenditure has been escalating in many 
firms, salesperson performance is still far from satisfactory (Zoltners et al., 2008, 
2013).This was reflected in the global surveys conducted by Accenture (Accenture, 
2010a, 2010b, 2012), Chief Sales Officers of countries including Malaysia, who 
participated in the global surveys, revealed that typically only the top 20% of the 
salespersons bring in more than 60% of the firm‘s revenue while the remaining 80% of 
the salespersons are considered ineffective (Accenture, 2010a, 2010b, 2012). In 
addition, the survey respondents collectively agreed that sales function is the most 
important functional area within their respective firms and they collectively 
emphasized that their top priority is to increase salesperson performance.  
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 Past research attempting to find the highest predictors of salesperson 
performance has not been successful because past research which focused in 
examining predictors related to salesperson‘s individual factor, organizational and 
environmental factors was still unclear and the results have been inconsistent 
(Jaramillo, Grisaffe, Chonko, & Roberts, 2009; Jaramillo, Ladik, Marshall, & Mulki, 
2007;Verbeke, Dietz, & Verwaal, 2011; Vinchur, Schippmann, Switzer, & Roth, 
1998).Attempts to investigate factors related to personal characteristics and attributes 
of individual salesperson performance have not been able to adequately explain the 
variance in salesperson performance too (Donassolo & de Matos, 2014; Morgan, 
2012; Singh & Koshy, 2010).    
 A sales manager is the organizational link between the upper management and 
the salesperson as the firm‘s vision and values are communicated through this link 
(Flaherty, Pappas, & Allison, 2014; Wieseke, Ahearne, Lam, & Dick, 2009). 
Typically, a sales manager executes the management strategies established by the 
organization (Baldauf, Cravens, & Piercy, 2001a). Scholars have noted that guidance 
provided by sales management may influence salesperson‘s selling behaviors (Weitz, 
Sujan, &Sujan, 1986). Hence, managerial practices conducted by a sales manager are 
reckoned as an importantfactor influencing salesperson performance and effectiveness 
(Brown & Petersen, 1993; Churchill et al., 1985; Dubinsky, 1999; Mulki, Jaramillo, & 
Locander, 2005; Weitz et al., 1986; Zallocco, Pullins, & Mallin, 2009) and in 
conducting marketing intelligence activities (Le Bon & Merunka, 2006).Despite 
knowing that factors associated with sales management are important and are the 
plausible explanation to salesperson performance, there are very few empirical studies 
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done on understanding the influence of sales managerial practices on salesperson 
performance (Avlonitis & Panagopoulos, 2007; Jaramillo & Mulki, 2008; Jaramillo et 
al., 2009). Cravens, Le Meunier-FitzHugh, and Piercy (2011) further supported that 
constructs related to what the sales managers do, such as managerial practices should 
be integrated into the studies of salesperson performance. Guenzi, Baldauf and 
Panagopoulos (2014) mentioned that other supervisory-related factors should be 
explored in addition to the extensively researched supervisory controls. Due to this, 
there is an emerging body of research focusing on factors related to sales management 
rather than the personal characteristics and attributes of the individual salesperson 
(Verbeke, Dietz, & Verwaal, 2011). Another emerging area of research is to 
understand what drivesa salesperson‘s selling behavior such as adaptive selling 
behavior (ASB) as individual selling behavior has a huge impact on salesperson 
performance and building long-term customer relationship (Franke & Park, 2006; 
Jaramillo et al., 2007). However, the number of empirical studies to understand how 
organizational or managerial factors influence salesperson performance through an 
intervening variable of salesperson‘s selling behavior is limited (Guenzi, Baldauf, & 
Panagopoulos, 2014). This motivates the present study to be conducted to examine the 
influence of managerial practices on salesperson performance with the mediating 
factor of salesperson‘s adaptive selling behavior (ASB).   
 As salespersons are usually independent and spending most of their time in the 
field, the appropriate managerial practices needs to be provided by the sales 
management to achieve optimum outcomes. Specifically, in examining the influence 
of managerial practices, there is very limited past research which examinesthe 
 
 
19 
combined influence of supervisory control (or supervision) and supervisory 
empowerment (or autonomy) simultaneously in the context of sales (Lambe, Webb, & 
Ishida, 2009; Simintiras, Ifie, Watkins, & Georgakas, 2013). In the past, supervisory 
control and empowerment were often perceived as contradictory but interrelated 
managerial approaches that often exist simultaneously, persist over time and create a 
certain amount of tension within the organization (Smith & Lewis, 2011). This is also 
known as the paradox in the management continuum model. However, the study 
conducted by Nash, Brown and Sutton (2014) suggested that control and 
empowerment can coexist. Nevertheless, studies examining the elements of paradox 
particularly in the context of sales have been generally lacking. Specifically, 
Simintiras, Ifie, Watkins, and Georgakas (2013) examined the direct relationship 
ofsupervisory control and empowerment on adaptive selling behaviors, whileLambe, 
Webb, and Ishida (2009) studied the simultaneous direct relationship of the influence 
of control and empowerment on sales team performance. Very few scholars explored 
the indirect relationship between the influence of control and empowerment on 
salesperson performance(Simintiras et al., 2013). Hence, it would beinteresting to 
explore the extent of supervisory control and empowerment influence on salesperson 
performance through the mediating factor of salesperson‘s adaptiveselling behavior. 
 The nature of a sales job often deals with different human natures and diverse 
selling situations. Timor and Tuzuner (2006) suggested that one of the factors which 
determine a salesperson‘s success in selling is the salesperson‘s interpersonal skills, 
which include social abilities such as persuasion, empathy and problem-solving. All 
these skills and qualities are related to the ability of the salespersons to manage their 
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own emotions and of others, and make use of this emotional information to the 
benefits of their interactions. These skills and abilities are referred to as emotional 
intelligence. Although emotional intelligence has been gaining popularity in sales 
force research, past research examining the moderating effect of emotional intelligence 
in the context of salesperson performance is still lacking (Kidwell, McFarland, & 
Avila, 2007; Kidwell, Hardesty, Murtha, & Sheng, 2011). Hence, it would be 
interesting to explore how emotional intelligence can play a moderating role in 
influencing the strengthand direction of the relationship.   
 Looking into the number of literature, there is limited sales literature published 
in comparison to marketing literature. Sales research is often regarded as a stepchild in 
the realm of marketing. Research in the area of sales force over the last ten years only 
accounts to 3% of the academic articles in four leading journals (Zoltners et al., 2008, 
2013). Of the forty eight articles published in 2011 by the Journal of Marketing, only 
one addressed the aspect of sales (Fogel, Hoffmeister, Rocco, & Strunk, 2012). 
Furthermore, past studies in the area of understanding the determinants of salesperson 
performance have been primarilyconducted in the Western countries (Alias, 2008; 
Baldauf, Cravens, & Piercy, 2001b) while the limited studies done in developing 
countries have been producing inconsistent results due to differences in political 
background, income, and culture (Piercy, Low, & Cravens, 2011). Hence, it would be 
worthwhile to conduct the present study to understand the influence of managerial 
practices on pharmaceutical salesperson performance in the context of Malaysian 
workforce.   
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 Specifically focused on the limited number of sales literature published in the 
field of pharmaceutical industry, studies related to pharmaceutical salesperson 
performance were mainly done in developed countries (Ahearne, Jones, Rapp, & 
Mathieu, 2008; Ahearne, Mathieu, & Rapp, 2005; Longino, 2007; Ryerson, 2008). It 
is evident that there is a dearth of research done in understanding factors affecting 
pharmaceutical salesperson performance in Malaysia. The most recent study was 
conducted by Kow and Yew (2012) who found that extrinsic factors and demographic 
factors motivate pharmaceutical salespersons in Malaysia. Other local researchers 
have studied various factors from different perspectives related to salesperson 
performance in different industries in Malaysia (Basir, 2007; Nor Azila, 2005; Omar, 
2008).    
 Based on the above-mentioned issues and problems, the present study seeks to 
address the gaps and aims to contribute to the existing body of knowledge in sales 
performance research. The present study attempts to find out the influence of 
managerial practices of supervisory control and supervisory empowerment on 
salesperson performance, with the mediating variable of salesperson‘s adaptive selling 
behavior and moderating influence of salesperson‘s emotional intelligence in the 
pharmaceutical industry in Malaysia. 
 
1.3 Preliminary Study 
In order to validate the problem statement and support the research objective of this 
study, a preliminary study was initiated with the task of eliciting information and 
obtaining opinions from sales managers in the pharmaceutical industry in Malaysia. 
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The preliminary study is in qualitative form with the aim to explore the complex and 
emerging business-related issues. The open-ended questions employed are of a semi-
structured type. The primary purpose of conducting the preliminary study is to obtain a 
more realistic picture of the current situation of salesperson performance and the 
related contributing factors from the perspective of the sales managers in the 
pharmaceutical industry in Malaysia.  
This preliminary study was conducted by means of electronic mail and then 
followed up with telephone calls for clarifications. The period of the preliminary study 
was from October 2014 to November 2014. Electronic mails were sent out to the 
Human Resource Department of the identified Malaysian firms to seek permission and 
subsequently forwarded to their firm‘s sales managers who agreed to participate. The 
pharmaceutical sales managers were asked to provide their opinions freely on their 
salesperson performance, managerial practices engaged, the importance of 
salesperson‘s adaptive selling behavior and the importance of salesperson‘s emotional 
intelligence. The preliminary study questionnaire is shown in Appendix A. 
Four pharmaceutical sales managers from different Malaysian pharmaceutical 
firms participated in the preliminary study and shared their opinions. The four 
Malaysian pharmaceutical firms are labelled as Firm A, Firm B, Firm C and Firm D. 
All four firms are large-scale Malaysian companies with a sizeable sales force 
covering the Malaysia market. 
Firm A has been established in Malaysia over seventy years from being a 
herbal medicine manufacturer to become a large-scale generic drugs manufacturer. 
Firm A is one of the local pioneers to market generic drugs to the overseas market. 
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Firm A was listed on the second board of the Kuala Lumpur Stock Exchange in 2005 
and subsequently transferred to the main board in 2006. In 2014, Firm A achieved an 
annual revenue of RM183 million with a gross profit of RM25 million. 
Firm B was founded in 1982 in Malaysia and is actively involved in the 
development of various types of medicines and health supplements. Firm B was listed 
on the main board of Kuala Lumpur Stock Exchange in 2007. Recognized for its 
leadership in delivering customer value and innovation, Firm B was bestowed twice 
the title Malaysia Pharmaceutical Company of The Year for 2011 and 2014 by Frost 
and Sullivan, a US-based consulting firm. In 2014, Firm B had an annual revenue of 
RM147 million with a gross profit of RM6 million.  
Firm C started in 1962 in Malaysia as a pharmaceutical retailer. It subsequently 
set up its manufacturing facility in Singapore in 1967 and relocated to Malaysia in 
1974. Firm C was listed on the second board of the Kuala Lumpur Stock Exchange in 
2000 and transferred to the main board in 2003. Firm C is currently involved in 
development, manufacturing, sales, distribution and wholesaling of a wide range of 
pharmaceutical products. In 2014, Firm C achieved an annual revenue of RM500 
million with a gross profit of RM116 million. 
Firm D is a privately held company under a parent company with its 
headquarters in the United States. It has a wide network of branches in Asia with 
strong warehouse and distribution facilities. Although it does not have local 
manufacturing plant in Malaysia, Firm D has a large sales force which markets a broad 
range of pharmaceutical products for a number of overseas principal companies. The 
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financial information of Firm D is not available publicly. Excerpts of their responses 
to each of the questions are presented in Appendix B. 
 
1.3.1 Findings and Implications of the Preliminary Study 
The preliminary study managed to obtain some key information pertaining to the 
actual situations and the issues faced by the pharmaceutical sales managers. Although 
only four sales managers participated in the preliminary study, the response from each 
of the sales managers was quite consistent and similar. The findings of the preliminary 
study revealed the following key information from the perspective of the sales 
managers. 
 
Salesperson performance 
The findings revealed that salespersons play a key role toward the success of the 
pharmaceutical firms. In general, the performance of the pharmaceutical salespersons 
varies. All the sales managers concurred that salesperson performance is a high 
priority and needs to be continuously improved to counter the competitive forces from 
rival firms. 
 
Managerial practices 
The findings revealed the concerns of the sales managers about their salespersons‘ 
performance and they have actively engaged in managerial practices with the aim of 
making sure their salespersons are capable of performing and achieving their 
respective firm‘s goals. In terms of the types of managerial practices engaged, they 
